Raymond James Maintains Outperform on Cytokinetics, Raises Price Target to $92

Cytokinetics, Incorporated +0.82%

Cytokinetics, Incorporated

CYTK

67.55

+0.82%

Raymond James analyst Sean McCutcheon maintains Cytokinetics (NASDAQ: CYTK) with a Outperform and raises the price target from $63 to $92.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via